Beryl Drugs Intrinsic Value
Beryl Drugs (BERLDRG) median intrinsic value is ₹40.88 from 4 valuation models (range ₹40–₹51), vs current price ₹20.44 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Also explore BERLDRG stock price history to track price trends across different timeframes.
BERLDRG Valuation Methods Summary — DCF, Graham Number & P/E
Beryl Drugs intrinsic value across 4 models vs current price ₹20.44 — upside/downside and value range per method. Browse BERLDRG annual financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | +95.7% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹40.88 | ₹36.79 - ₹44.97 | +100.0% | Revenue/Share: ₹38.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.00 | ₹36.00 - ₹44.00 | +95.7% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹51.10 | ₹40.88 - ₹61.32 | +150.0% | CF Growth: 5.0%, Discount: 15% |
BERLDRG Intrinsic Value vs Market Price — All Valuation Models
Beryl Drugs fair value range ₹40–₹51 vs current market price ₹20.44 across 4 valuation models. For current market price and key ratios, visit Beryl Drugs screener.
BERLDRG Intrinsic Value Analysis — Undervalued or Overvalued?
Beryl Drugs median intrinsic value ₹40.88, current price ₹20.44 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of BERLDRG?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Beryl Drugs (BERLDRG) is ₹40.88 (median value). With the current market price of ₹20.44, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹40.00 to ₹51.10, indicating ₹40.00 - ₹51.10.
Is BERLDRG undervalued or overvalued?
Based on our multi-method analysis, Beryl Drugs (BERLDRG) appears to be trading below calculated value by approximately 100.0%.
BERLDRG Financial Health — Key Ratios vs Industry Benchmarks
Beryl Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Asset Turnover Ratio | 1.19x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
BERLDRG Cash Flow Quality — Operating & Free Cash Flow
Beryl Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |